A caution regarding high-dose biotin therapy: misdiagnosis of hyperthyroidism in euthyroid patients

Medical Journal of Australia

Volumn 205, Issue 4, 2016, Pages

  Trambas, Christina M ^a   Sikaris, Kenneth A ^a   Lu, Zhong X ^a,b  

^a MELBOURNE PATHOLOGY   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTIN; THYROID HORMONE;

AUSTRALIA; BLOOD; DIAGNOSTIC ERROR; DOSE RESPONSE; HUMAN; HYPERTHYROIDISM; INTERDISCIPLINARY COMMUNICATION; INTERSECTORAL COLLABORATION; MULTIPLE SCLEROSIS; THYROID FUNCTION TEST;

AUSTRALIA; BIOTIN; DIAGNOSTIC ERRORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPERTHYROIDISM; INTERDISCIPLINARY COMMUNICATION; INTERSECTORAL COLLABORATION; MULTIPLE SCLEROSIS; THYROID FUNCTION TESTS; THYROID HORMONES;

EID: 84992730082     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/MJA16.00544     Document Type: Letter

References (5)

1. Sedel F, Papeix C, Bellanger A, et al. High doses of biotin in chronic progressive multiple sclerosis: a pilot study. Mult Scler Relat Disord 2015; 4: 159-169.
2. Henry JG, Sobki S, Arafat N. Interference by biotin therapy on measurement of TSH and FT4 by enzyme immunoassay on Boehringer Mannheim ES700 analyser. Ann Clin Biochem 1996; 33: 162-163.
3. Wijeratne NG, Doery JCG, Lu ZX. Positive and negative interference in immunoassays following biotin ingestion: a pharmacokinetic study. Pathology 2012; 44: 674-675.
4. Barbesino G. Misdiagnosis of Graves’ disease with apparent severe hyperthyroidism in a patient taking biotin megadoses. Thyroid 2016; 26: 860-863.
5. Peyro Saint Paul L, Debruyne D, Bernard D, et al. Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis. Expert Opin Drug Metab Toxicol 2016; 12: 327-344.